Teladoc Health (NYSE:TDOC) Price Target Lowered to $16.00 at Stifel Nicolaus

Teladoc Health (NYSE:TDOC) had its price objective decreased by Stifel Nicolaus from $21.00 to $16.00 in a research note published on Friday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the health services provider’s stock.

Several other analysts have also recently commented on the stock. Needham & Company LLC reaffirmed a hold rating on shares of Teladoc Health in a research note on Friday. Barclays lowered their target price on shares of Teladoc Health from $25.00 to $20.00 and set an overweight rating for the company in a research note on Friday. Cantor Fitzgerald started coverage on shares of Teladoc Health in a research note on Thursday, February 29th. They issued an overweight rating and a $22.00 target price for the company. SVB Leerink started coverage on shares of Teladoc Health in a research note on Monday, February 26th. They issued a market perform rating and a $17.00 target price for the company. Finally, Royal Bank of Canada lowered their target price on shares of Teladoc Health from $30.00 to $25.00 and set an outperform rating for the company in a research note on Wednesday, February 21st. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Teladoc Health has a consensus rating of Hold and an average target price of $19.00.

Teladoc Health Trading Down 2.4 %

Shares of TDOC opened at $13.01 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. The firm has a 50 day simple moving average of $14.85 and a 200-day simple moving average of $17.71. Teladoc Health has a 1-year low of $12.65 and a 1-year high of $30.41. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -9.23 and a beta of 0.94.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The business had revenue of $646.13 million for the quarter, compared to analysts’ expectations of $637.31 million. During the same period last year, the business earned ($0.37) earnings per share. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. Equities analysts forecast that Teladoc Health will post -1.06 EPS for the current fiscal year.

Insider Activity

In related news, CTO Nikolaos P. Nanis sold 2,866 shares of Teladoc Health stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $41,614.32. Following the transaction, the chief technology officer now owns 69,850 shares in the company, valued at approximately $1,014,222. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CTO Nikolaos P. Nanis sold 2,866 shares of Teladoc Health stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $41,614.32. Following the transaction, the chief technology officer now owns 69,850 shares in the company, valued at approximately $1,014,222. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew Turitz sold 6,190 shares of Teladoc Health stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $89,878.80. Following the transaction, the executive vice president now owns 39,429 shares in the company, valued at approximately $572,509.08. The disclosure for this sale can be found here. Insiders sold 135,441 shares of company stock valued at $2,038,251 in the last ninety days. Company insiders own 1.63% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ICA Group Wealth Management LLC acquired a new position in Teladoc Health in the 4th quarter worth $28,000. Hexagon Capital Partners LLC lifted its holdings in Teladoc Health by 204.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after buying an additional 1,065 shares in the last quarter. RIA Advisory Group LLC acquired a new position in Teladoc Health in the 4th quarter worth $36,000. GAMMA Investing LLC acquired a new position in Teladoc Health in the 4th quarter worth $41,000. Finally, Principal Securities Inc. acquired a new position in Teladoc Health in the 4th quarter worth $45,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.